The FemTech industry’s approach to PMOS

T he global decision to rename Polycystic Ovary Syndrome (PCOS) as Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a culmination of a decade-long collaboration between doctors, researchers, and patient groups. Led by Professor Helena Teede, Director of the Monash Centre for Health Research and Implementation in Melbourne, the rationale for the change was published in The Lancet last month. At the heart of the renaming was a growing recognition that the term PCOS could not capture the condition’s complexity, and reduced it to a reproductive disorder centred on the ovaries. It is a long overdue acknowledgement of the condition’s multisystem nature as PMOS manifests through a wide range of endocrine, metabolic, reproductive, psychological, and dermatological symptoms.